Jiangsu Nhwa Pharmaceutical Corporation Ltd. is an integrated pharmaceutical corporation conducting technology, industry and distribution, and is the designated manufacturer of psychotropic drugs by National Ministry of Health. The company has been entitled as the National Hi-tech Enterprise and ranked among National Top 100 Pharmaceutical Enterprises, with Post-Doctoral Research Center, Post-Doctoral Innovation Center and Nationally Designated Technology Center, It's a public corporation listed on Shenzhen SME board, and the brandcertified corporation of International Environmental Standard System (ISO14000). Nhwa has been appraised as the famous brand in China.

The corporation mainly deals in manufacturing the Central Nervous System (CNS) medicines, owning two large-scale pharmaceutical production facilities of APIs and Drugs, which cover a total of over 400 mu (1 mu equivalents to 667 sq.m.). The major products include tens of dosage forms of tablets, capsules, small dose injections, freeze-dried powders, and Chinese medicines. Currently, there are 27 kinds of APIs with annual yield of 350 tons and 90 kinds of dosage forms with annual production capacity of 2 billion tablets, 300 million capsules and 100 million injections.

Nhwa is the sole domestic pharmaceutical corporation focusing on CNS medicine and devoting itself to the segmented market, and has developed three series product lines of psychiatrical, anesthetic and neurological medicines, which cover the categories of anti-anxiety agent, anti-depressant, anti-psychopathic drug, antiepileptic drug, hypnotic, intravenous anesthetics and respiratory excitant, etc. So far, Nhwa can provide the most varieties of CNS medicine in China. The sales of CNS medicine in clinic field take a leading position among the domestic corporations, with 88.4% of intravenous anesthetics market share.

As enhancing R&D of CNS drugs in recent years, the corporation has been spending tremendous efforts in researching cardio-cerebral vascular medicine with intellectual property rights, so as to meet the market demand, promote the scientific level and achieve the extensive development.

Through the R&D process of new products, the corporation emphasizes on the combination of production, academy and research. By establishing the R&D platform with the institutes famed by advanced science and technology in CNS field, such as the Academy of Military Medical Sciences, Shanghai Institute of Pharmaceutical Industry and Huazhong University of Science and Technology, the corporation can catch up with the international trend of new medicine in R&D capacity and speed of new medicine with independent intellectual property rights.

With the responsibility of improving the mental health of human beings, the company increases innovation and struggles for the transitions from reproduction of new medicine to independent innovation, from domestic operation to international operation, and from products oriented to brand oriented, so as to explore the perfect solution for the release of physical and mental pain of people, thus, strives toward the biggest domestic CNS drugs manufacturer as well as the international famed CNS drugs provider.